|
|
 |
|
Viewing report
|
|
|
|
Scrip R&D Databook 2006
Informa Healthcare, Jan 2006, Pages: 427
Scrip R&D Databook 2006 allows users to identify important trends within pharmaceutical R&D and benchmark their own performance. Beginning with an industry overview of R&D costs, investment levels and staffing levels, the report will then provide a comprehensive analysis of R&D trends by therapeutics class, biotechnology products, and development status.
The report will review the R&D profiles of selected leading companies. Also the inclusion of data from PharmaPredict will allow users to compare the R&D success rates of drugs with different therapeutic activities or from different companies. It will also provide an accurate estimate of how long a drug will take to reach the market.
This report will enable you to:
- Benchmark against industry performance
- Evaluate product investment potential
- Predict how long it will take your product to reach the market
- Compare therapeutic products across companies
- Get ahead of R&D trends, instead of spending time and resources in research
The Pharmaceutical R&D Databook is intended as a strategic reference guide to the important trends in pharmaceutical R&D, as well as providing the means to benchmark your company’s performance. From an examination of global R&D investment and productivity, to a breakdown of R&D trends in every major therapeutic class, the Databook provides a comprehensive review of the current R&D environment and puts it into context with an historical analysis.
Chapters 1 and 2 of the Databook look at the trends in R&D expenditure in the major markets, changes in employment patterns and productivity levels in relation to pharmaceutical sales. The US remains the powerhouse of the pharmaceutical and biotechnology industries, whilst Europe struggles to keep up. In Japan, the economic hardships of recent years have been alleviated and the Japanese pharmaceutical industry is beginning to see signs of recovery. Chapter 3 reviews the outsourcing industry and examines its role in pharmaceutical R&D.
Chapters 4 to 9 analyse the trends in R&D by examining the therapeutic focus of selected companies, preclinical compounds, biotechnology compounds, compounds in clinical development for every major therapy class, and licensing activities. The data for these sections are collated from the extensive resources of the Pharmaprojects database, which has been tracking pipeline drugs since 1980 and includes every novel drug reported since then. The information from these sections will enable the reader to:
- Assess major trends in pharmaceuticals R&D, by therapeutic categories and novel development strategies;
- Compare the number of biotechnology products in each development Phase, between 2001 to 2005;
- Compare development ranges across companies.
Chapter 10 provides extensive attrition and time-in-development data for the major therapeutic categories. This information was collated by searching Pharmapredict. Pharmapredict, the companion database to Pharmaprojects, is based on data extracted from Pharmaprojects, and combined with previously unpublished data, such as the dates that drugs entered each of the Phases of R&D and the Phase at which unsuccessful drugs were dropped, to provide extensive benchmarking data.
In chapter 10, the R&D development times compare the time that therapies or pharmacological strategies spend in development. The information is derived from data collected since 1989 and measures the time a drug spends in each of the Phases of development. The percentage success rates are also calculated as an historical average. However, the database includes data collected since 1980. Drugs that have either been successful (launched) or unsuccessful (discontinued) are included. Drugs that are currently in development, i.e. are not yet successful or unsuccessful, are not included.
Customers who bought this item also bought
Bio/Pharmaceutical R&D Statistical Sourcebook 2007/2008
Bio/Pharma R&D Statistical Sourcebook 2008/2009
Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI
Pharmaceutical R&D Statistical Sourcebook 2005/2006
Innovative Drug R&D in China
New Approaches to Pharma R&D: Evolving Strategies to Rejuvenate R&D Efficiency
Bio/Pharmaceutical R&D Statistical Sourcebook 2006/2007
Rethinking Pharmaceutical R&D: Will New Strategies Yield a Pipeline Payoff?
R&D Strategies: Incremental improvements and paradigm shifts in strategy are both necessary to boost productivity
Strategies for Innovation in Pharmaceutical R&D: Enhancing R&D Through Biotech Alliances and CRO Outsourcing
Pharmaceutical Mergers and Acquisitions
Innovative Strategies and Models for R&D Success: The Evolving Networked Pharma Company
|
|
|
|
